Coming Soon

TNG462-C102: Early Study of a New Drug Combo for Pancreatic or Lung Cancer with MTAP Loss and RAS Mutation

This study is exploring whether the new drug combo of TNG462 + RMC‑6236/9805 can be safely given to patients with tough pancreatic or lung cancers that have specific genetic markers, and if it shows promising early signs of fighting the cancer.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

United States (Nationwide)

Additional Study Information

Principal Investigator

Shetal Patel
Medicine- Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lung, Pancreatic, Phase 1 Trials (all cancers))

IRB Number

25-1449

ClinicalTrials.gov

NCT06922591

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.